Big Pharma announces major side effect – has product pulled by government

PHARMACEUTICAL company AstraZeneca has admitted for the first time that its Covid-19 vaccine can cause rare side effects such as thrombosis. 

The admission came in court documents that were submitted in February to the High Court in the United Kingdom as part of a class-action lawsuit. 

As reported by British daily The Telegraph, AstraZeneca accepted that its Covid vaccine ‘can, in very rare cases, cause TTS’, which stands for Thrombosis with Thrombocytopenia Syndrome. This causes people to have blood clots as well as a low blood platelet count. 

Despite Britain not being in the European Union any more, the EU has been paying attention.

On 27 March 2024, the European Commission withdrew the marketing authorisation for Vaxzevria (COVID 19 Vaccine (ChAdOx1 S [recombinant])) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, AstraZeneca AB, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Vaxzevria was granted conditional marketing authorisation in the EU on 29 January 2021 for active immunisation against coronavirus disease 2019 (COVID-19). The conditional marketing authorisation was switched to a standard marketing authorisation, valid for 5 years, on 31 October 2022.

The European Public Assessment Report (EPAR) for Vaxzevria will be updated to indicate that the marketing authorisation is no longer valid. More here.